GRFS:NGS-Grifols S.A. (USD)

EQUITY | Drug Manufacturers - General | Nasdaq Global Select

Last Closing

USD 8.88

Change

-0.07 (-0.78)%

Market Cap

USD 10.54B

Volume

0.29M

Analyst Target

USD 25.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Grifols SA is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. It operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+0.29 (+0.37%)

USD 241.92B
AMGN Amgen Inc

-0.46 (-0.14%)

USD 173.38B
SNY Sanofi ADR

-0.02 (-0.03%)

USD 144.83B
GILD Gilead Sciences Inc

+0.23 (+0.28%)

USD 104.09B
BIIB Biogen Inc

-0.83 (-0.43%)

USD 28.36B
AMRN Amarin Corporation PLC

+0.02 (+3.76%)

USD 0.25B
MIRA MIRA Pharmaceuticals, Inc. Com..

+0.14 (+12.07%)

USD 0.02B
SCLX Scilex Holding Company

-0.02 (-1.70%)

N/A
SCLXW Scilex Holding Company

-0.04 (-15.38%)

N/A

ETFs Containing GRFS

BINV 2.15 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.18% 45% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.18% 45% F 29% F
Trailing 12 Months  
Capital Gain -1.44% 55% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.44% 55% F 40% F
Trailing 5 Years  
Capital Gain -54.62% 21% F 23% F
Dividend Return 4.39% 10% F 12% F
Total Return -50.23% 21% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain -18.60% N/A N/A 18% F
Dividend Return -17.70% N/A N/A 18% F
Total Return 0.90% N/A N/A 22% F
Risk Return Profile  
Volatility (Standard Deviation) 19.84% N/A N/A 77% C+
Risk Adjusted Return -89.21% N/A N/A 8% B-
Market Capitalization 10.54B 31% F 91% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - General) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.10 64% 30%
Price/Book Ratio 0.98 81% 73%
Price / Cash Flow Ratio 34.25 19% 9%
Price/Free Cash Flow Ratio 10.72 69% 32%
Management Effectiveness  
Return on Equity 2.82% 31% 63%
Return on Invested Capital 4.68% 31% 67%
Return on Assets 2.47% 31% 76%
Debt to Equity Ratio 140.98% 25% 16%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector